Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
MitraClip: impact on symptoms and quality of life
Session:
Posters 1 - Écran 6 - Cardiologia de Intervenção
Speaker:
Tiago Graça Rodrigues
Congress:
CPC 2019
Topic:
H. Interventional Cardiology and Cardiovascular Surgery
Theme:
25. Interventional Cardiology
Subtheme:
25.3 Non-coronary Cardiac Intervention
Session Type:
Posters
FP Number:
---
Authors:
Tiago Graça Rodrigues; E. Infante de Oliveira; Ana Rita Francisco; P. Carrilho Ferreira; Miguel Nobre Menezes; Joana Rigueira; Inês Aguiar Ricardo; Nelson P. Cunha; Rafael Santos; Afonso Nunes Ferreira; Fausto José Pinto; Pedro Canas Da Silva
Abstract
<p><strong>Introduction</strong>: In patients with severe mitral regurgitation (MR) and prohibitive surgical risk, percutaneous mitral valve repair seems to be associated with symptomatic and functional improvement. </p> <p><strong>Aim</strong>: To assess the impact on quality of life and symptoms of percutaneous mitral repair in "real world" patients. </p> <p><strong>Methods</strong>: A prospective unicentric record registry of consecutive patients undergoing percutaneous MR repair with MitraClip from 2013 to 2018. Demographic, clinical (including functional class (NYHA) and Minnesota Quality of Life (QoL) questionnaire), and echocardiographic were evaluated. Clinical, face-to-face or telephpne follow-up with reassessment of functional class and QoL score was performed. For statistical analysis, the chi-square and Student's T tests were used. </p> <p><strong>Results</strong>: 51 procedures (mean age 71.8 ± 13.5 years, 30 men) were performed in patients with symptomatic MR grade III or IV. 14 patients (27.5%) had primary MR and 37 (72.5%) had secondary MR. The success rate per patient was 92.0%. The complication rate was 7.7% (n = 4, 2 procedural failures, 1 stroke and 1 vascular complication).</p> <p>During an average follow-up (FUP) of 615 ± 613 days, there were 17 deaths (33.3%). Most patients were in NYHA III functional class (34 patients, 66.7%) or IV (13 patients, 25.5%), with a statistically significant improvement of the functional class in the short-term postoperative period (3.2 ± 0.6 vs 2.0 ± 0.7, p <0.001), which was maintained throughout the FUP (2.1 ± 1.0 vs. 2.0 ± 0.7, p = 0.329). At the end of the FUP, most patients were in NYHA II functional class (22 patients, 43.1%) or I (9 patients, 17.6%), with only one NYHA IV class. There was also a significant improvement in quality of life, maintained during the long-term FUP (43.7 ± 19.1 vs 22.6 ± 16.6, p <0.001), as measured by the QoL-Minnesota score.</p> <p>The symptomatic improvement was associated with lower regurgitant volume (69.7 ± 25.8 mL vs 113.3 ± 71.5 mL, p = 0.031) and EROA (0.4 ± 0.2 cm2 vs 0.6 ± 0, 4 cm 2, p = 0.036). No other clinical or echocardiographic predictors of symptomatic improvement were identified.</p> <p><br /> <strong>Conclusion</strong>: The implementation of MitraClip for treatment of severe MR has led to symptomatic improvement and quality of life in real-world patients. As opposed to LVEF, the lower MR severity was a predictor of symptomatic improvement. Thus, it is important to reaffirm percutaneous repair as a complementary treatment to optimized medical therapy in patients with severe MR and surgical contraindication.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site